Scorpius Secures Multimillion-Dollar Biotech Contract for Phase 2 Program

NightHawk Biosciences, a company specializing in contract development and manufacturing services (CDMO), has secured a substantial contract for its subsidiary, Scorpius BioManufacturing. The contract involves providing comprehensive services, including process development, analytical support, and cGMP manufacturing, for a Phase 2 clinical program of a publicly traded biotechnology firm.

The CEO of NightHawk Biosciences, Jeff Wolf, expressed pride in being chosen to contribute to the advancement of a therapy that could save lives. He highlighted Scorpius' clientele, which includes companies with FDA Orphan Drug Designations, and noted the suitability of the San Antonio facility for such critical projects. The new client, previously associated with a larger CDMO, has opted for Scorpius due to its adaptability, dedicated service, and commitment to project timelines. The work, which entails manufacturing a monoclonal antibody, is scheduled for completion in 2024.

Wolf also reflected on the achievements of Scorpius in 2023, its first full year of operation, and expressed enthusiasm for the continued growth of demand for their biomanufacturing services.

Scorpius BioManufacturing, a division of NightHawk Biosciences, offers a wide range of services including analytical testing, process development, and manufacturing from its advanced facilities in San Antonio, Texas. The team at Scorpius is experienced and committed to transparent collaboration and high-quality biomanufacturing services.